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Abstract 
Introduction: The development of thrombosis is multifactorial in Antiphospholipid Syndrome 
(APS), with other inherited and acquired risk factors influencing the thrombotic profile. While inherited 
thrombophilia are still rare among APS patients, some works suggest a higher prevalence of C and S 
Proteins deficiencies and factor V Leiden mutation in these patients compared to the general population. 
Nevertheless, the exact frequency and clinical implications of the presence of these prothrombotic factors 
in APS are still poorly characterized. Methods: All patients followed in an Autoimmune Diseases 
consultation with a diagnosis of APS fulfilling the Sidney revised criteria were included. Data regarding 
inherited thrombophilia was collected - Activated protein C resistance (APCR); Leiden V Factor 
mutation; C and S proteins deficiencies; Prothrombin G20210A  mutation; and Antithrombin III 
deficiency. Results: A total of 75 patients were analysed, with 65.3% corresponding to primary APS. The 
mean age of the study sample was 40 ± 9.4 years and the mean duration of disease was of 6.57 years ± 
4.78 years. Seventeen (22.7%) patients exhibited an inherited thrombophilia: 9 (16.1%) S protein  
deficiency, 5 (10.2%) APCR, 5 (8.5%) antithrombin III deficiency, 4 (7.1%) C protein deficiency, 2 
(4.5%) prothrombin G20210A  mutation and 1 (2.0%) Leiden V factor mutation. The presence of 
inherited thrombophilia did not show statistically significant association with clinical manifestations or 
recurrence of events. Conclusion: Although with a significant prevalence in the studied sample, the 
presence of inherited thrombophilia did not display a significant clinical implication. However, positive 
findings might have been undermined due to the reduced sample size originating an underpowered study. 
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Introduction 
Antiphospholipid Syndrome (APS) is defined by the presence of venous and/or arterial 
thrombosis and/or obstetrical manifestations in combination with the persistent positivity of 
antiphospholipid antibodies (aPL) [1,2].  
The development of thrombosis is multifactorial in APS, with other inherited and acquired risk 
factors influencing the thrombotic profile [3]. The exact prevalence and clinical implications of other 
prothrombotic factors are still poorly characterized. Previous data suggests that anticoagulant deficiencies 
are rare among APS patients but, albeit with conflicting results, some works indicate that C and S proteins 
deficiencies and Leiden V factor mutations are more frequent when compared to non-APS patients [4-8]. 
A study hints a role of Leiden V factor mutation in increased risk of arterial and venous thrombosis in 
APS patients [6], but further works do not confirm this association [8,4]. Regarding prothrombin 
G20210A mutation, available evidence does not suggest an increased prevalence nor a role as an 
additional thrombotic risk factor in APS [6,8,4]. 
APS carries significant morbidity and mortality without the appropriate management, but the 
recommended therapy, anticoagulation, carries itself significant morbidity and considerable change in the 
patient´s daily life [9]. 
Important questions remain unanswered on this field, namely what determines the type of APS 
clinical manifestation (arterial versus venous versus obstetric) and why some patients recur despite 
anticoagulation. Deepening the knowledge on other prothrombotic factors’ influence on APS clinical 
spectrum is still a goal for physicians who fight to improve therapeutic regimens, outcomes and patient’s 
quality of life. 
The aim of our study was to evaluate the presence of other prothrombotic factors and their clinical 
and prognostic implications, and also to verify the role of such risk factors in thrombosis recurrence. In 
addition we assessed for the presence of non-criteria clinical manifestations. 
 
1. Patients and methods 
A cohort analysis (with descriptive and analytical components) was conducted following approval 
by the Ethics Committee of Centro Hospitalar de São João. 
The study included male and female Caucasian patients, with ages between 18 and 65 years, 
selected as a convenience sample from the Autoimmune Diseases Outpatients Clinic of the Internal 
Medicine Department of Centro Hospitalar de João, Porto, Portugal.  
Inclusion criteria: patients with a diagnosis of “classic” APS based on the Sidney revised criteria.  
A total of 75 patients have been recruited, which were characterized by revising their records as 
well as laboratory and complementary imaging exams.  
All patients recruited strictly met the current classification criteria for APS [2]. Population 
characterization was performed by revising medical records as well as laboratory and imaging exams, 
and included in a database. Data registered comprised: (1) gender, (2) race, (3) age at diagnosis, (4) 
underlying autoimmune diseases, if any, (5) clinical manifestations at onset (defined as index event) and 
thereafter (6) clinical non-criteria manifestations, (7) laboratory profile including screening for inherited 
thrombophilia and immunological profile (antiphospholipid antibodies, aPL – namely β2glycoprotein1, 
 
 
anticardiolipin and lupus anticoagulant, ANA; ANA pattern; anti-SSa; anti-SSb; anti-Scl70; anti-
U1RNP; anti-centromere; ANCA; Rheumatoid Factor), (8) cardiovascular risk factors (hypertension; 
dyslipidemia; diabetes; obesity; hyperurucemia, smoking; (9) use of combined oral contraceptives 
(COCs), (10) therapy before and after disease onset/relapse. 
 
2. Statistical analysis 
All data and variables were in a database. Statistical analysis was performed by using SPSS 22 (IBM 
Analytics). In the analytical field, variables were analyzed using Chi-square and Fisher’s Exact tests for 
categorical variables.  
 
3. Results 
General Characteristics. The study included 75 patients, 61 female (80%) and 14 male (20%), with 
a mean age of 40.03 + 9.41 years old (30.61 – 49.44) and a mean disease duration of 6.57 + 4.78 years 
(1.79 – 11.35). 65.3% of patients (n=49) corresponded to primary APS, with the remaining being 
associated with other autoimmune disease, mostly Systemic Lupus Erythematosus (SLE) – 16 patients, 
21.3%. Regarding comorbidities, the most frequent cardiovascular risk factor among all analyzed 
variables was dyslipidemia (n=29, 38.7%). Twenty-four patients (47%) were taking COCs. Detailed 
information is presented in Table VII of “Attachments” section. 
Concerning thrombotic events, the most frequent index event among APS-patients was venous 
thrombosis, present in 47 (62.7%) patients, while arterial thrombosis occurred in 13 (17.3%) patients. 
Deep vein thrombosis corresponded to the most significant venous event, present in 36 patients (48%),  
followed by cerebral venous sinus thrombosis (n=12, 16%) and pulmonary embolism (n=10, 13.3%). On 
the arterial side, stroke was the most significant manifestation (n=6, 8%), followed by acute myocardial 
infarction (n=3, 4%) and transient ischemic attack (n=2, 2.7%). Regarding female patients, 36.1% of 
them presented with obstetric morbidity – 24.6% suffered from unexplained fetal death after 10th week of 
gestation; 6.6% had one or more premature births before 34 weeks and 1.6% experienced three or more 
embryonic pregnancy losses. 
Considering recurrence of thrombotic events, it occurred in 16% (n=12) of patients with venous 
thrombosis being the most frequent recurrent event. Complete description of recurrence is displayed in 
Table I. 
Analysing the group of patients with SLE-associated APS (n=16), venous thrombosis was present in 
11 (68.8%) patients, while arterial thrombosis occurred in 3 (18.8%) patients and obstetric morbidity in 6 
(46.2%) of patients. 
 
 
 
 
 
 
 
 
 
Recurrent Event Nº of cases (%) 
Venous thrombosis 14 (18.7%) 
Deep vein thrombosis 13 (17.3%) 
Pulmonary embolism 2 (2.7%) 
Cerebral venous sinus thrombosis 1 (1.3%) 
Axillary vein thrombosis 1 (1.3%) 
Ocular thrombosis 1 (1.3%) 
Arterial thrombosis   2 (2.6%) 
Ischemic stroke 1 (1.3%) 
Transient Ischemic Attack  1 (1.3%) 
Obstetric morbidity 5 (6.7%) 
Unexplained fetal death at 10 or more gestation weeks 3 (4.0%) 
One or more premature births before 34 weeks 2 (2.7%) 
 
Table I. Event recurrence among APS-patients. 
 
Regarding non-criteria clinical manifestations, the most common clinical entities observed were 
migraine (n=16, 21.3%) and thrombocytopenia (n=12, 16%). Less commonly, there were cases of renal 
microangiopathy (n=2, 2.7%), seizures (n=2, 2.7%), alveolar hemorrhage (n=2, 2.7%), livedo reticularis 
(n=1, 1.3%), memory lapses and cognitive impairment (n=1, 1.3%), and bone osteonecrosis (n=1, 1.3%). 
No patients displayed past events of transverse myelitis or chorea, ARDS, heart valve dysfunction or 
skin pseudovasculitis.  Detailed data is presented in the “Attachments” section, tables III and IV. 
 
Inherited thrombophilia and remaining immunological profile. Laboratory tests for inherited 
thrombophilia were not available in all patients, hence reducing the sample size in the analysis of these 
variables (levels of S Protein and C protein n=56, prothrombin G20210A mutation n= 44, Antithrombin 
III n=59, Leiden V factor n=51, and ACRP n=49). In the studied sample, 17 (22.7%) patients exhibited at 
least one inherited thrombophilia. The prevalence of each thrombophilia among the studied population is 
presented in table II.  
Thrombophilia 
Nº of patients 
(%) 
Patients with obstetric 
morbidity (n=22) 
S Protein Deficiency (n=56) 9 (16.1%) 4 (18.2%) 
Activated C-reactive protein (n=49) 5 (10.2%) 3 (13.6%) 
Antithrombin III (n=59) 5 (8.5%) 1 (4.5%) 
C Protein Deficiency (n=56) 4 (7.1%) 0 
Prothrombin gene mutation (n=44) 2 (4.5%) 1 (4.5%) 
Leiden V Factor (n=51) 1 (2.0%) 0 
 
Table II. Prevalence of thrombophilia among the studied patients 
 
Concerning the aPL profile, isolated lupus anticoagulant positivity occurred in 22  patients (29.3%), 
isolated anticardiolipin antibodies positivity in 14 (20%) and isolated β2glycoprotein1 antibodies 
positivity in 11 (14%). Double positivity for β2glycoprotein1 and antiocardiolipin antibodies occurred in 
7 patients (9.3%), double positivity for β2glycoprotein1 antibodies and lupus anticoagulant also in 7 
(9.3%) and double positivity for anticoagulant antibodies and lupus anticoagulant in 6 (8%). Triple 
 
 
positivity occurred in 8 patients (10.7%). Persistent positivity for aPL antibodies (accounted as more 
than 3 positive determinations) occurred in 24 patients (32%). 
Referring to the remaining immunological profile, ANA antibodies were present in 54.7% of the 
patients included in this study. The most frequent pattern was speckled (29.3%), followed by 
homogeneous (14.7%), nucleolar (9.3%) and mid-body (1.3%). Other autoantibodies usually requested 
as part of an autoimmune profile were almost always negative.  More detailed information is presented in 
table V in the “Attachments” section. 
 
Therapeutic approach. Fifty-eight  patients were under oral anticoagulation (warfarine), 28 with 
aspirin and one taking clopidogrel. Twenty-five patients were under therapy with hydroxychloroquine. 
Among the 12 patients that recurred, 9 (75%) were under under oral anticoagulation. 
 
Correlation between inherited thrombophilia, cardiovascular risk factors and clinical outcomes. 
The presence of inherited thrombophilia did not show statistically significant association with specific 
clinical manifestations or with recurrence of events. However, regarding non-criteria manifestation, a 
statistically significant association was found between APS-patients with C-protein deficiency and the 
occurrence of Raynaud phenomenon, with a p-value of 0.011 (determined using Fisher’s exact test). 
Concerning classical cardiovascular risk factors and their influence on patients’ prognosis, no statistically 
significant association with the type of clinical event nor with recurrence frequency was found. 
We present more detailed data in “Attachments”, tables VII and VIII. 
 
Discussion  
 In this study APS patients were evaluated for the presence of inherited thrombophilia (namely C 
and S Proteins deficiencies, Leiden V factor mutation, APCR, Antithrombin III deficiency and 
prothrombin G20210A mutation), cardiovascular risk factors and association with other autoimmune 
disease. The presence of inherited thrombophilia and/or cardiovascular risk factors were not associated 
with increased risk for recurrence neither with the type of vascular events. Furthermore, the presence of 
other autoimmune disease did not display any particular clinical significance among these patients.  
The literature surrounding the domain of other prothrombotic factors in APS is markedly scarce. 
Firstly, the rarity of these entities undermines the recruitment of large study samples. Secondly, a number 
of factors affects the determination of these parameters -  in acute thrombotic events or in patients under 
oral anticoagulation, natural anticoagulant activities counting may be decreased. Our study, albeit 
undersized, has tried to address these matters in a coherent manner: in order to avoid misdiagnosis of 
inherited C or S proteins deficiencies, these parameters were determined when patients were not under 
anticoagulation and with appropriate separation from an acute event.  
As the most striking finding of this study comes the significant prevalence of inherited 
thrombophilia, with 22.7% of patients displaying at least one of these parameters. Previous reports in the 
literature stated a prevalence of Factor V Leiden ranging from 1.3 to 13% and Prothrombin G20210A 
mutation ranging from 2.7% to 6.5% in APS [4,6,8]. Our values rank among these range (2% and 4.5%, 
respectively), but are not superior to those reported in the general population (2 to 8% for Factor V 
 
 
Leiden in Caucasians and 0 to 15.9% for Prothrombin G20210A mutation in different ethnic groups) 
[10,6,11,12]. In our cohort, nevertheless, there was a significant prevalence of other thrombophilia, such 
as S Protein deficiency (16.1%), RCPA (10.2%), Antithrombin III deficiency (8.5%) and C Protein 
deficiency (7.1%). 
In fact, no association was found between the presence of hereditary thrombophilia and specific 
thrombotic manifestations or recurrent events. Although these findings should be analyzed with care due 
to the reduced sample size, they add strength to the hypothesis that the presence of hereditary 
thrombophilia do not significantly increase the thrombotic risk of APS patients, and that no specific 
therapeutic measure needs to be contemplated in these patients. 
Inherited thrombophilia are also linked to adverse pregnancy outcomes [13]. Studies have suggested 
that pregnant women with antithrombin III deficiency have a higher incidence of obstetric morbidity 
when compared to women without thrombophilia [14,15]. In the present work no statistically significant 
association was found regarding these outcomes. 
In our study, we also evaluate the prevalence and potential associations with typical cardiovascular 
risk factors in criteria and non-criteria manifestations and event recurrence. A statistically significant 
association was not found, as in previous works, suggesting that they might not play a major role in 
thrombotic events of APS-patients [1,16]. 
Considering non-criteria manifestations, our study showed a prevalence of 16% of 
thrombocytopenia, a less prominent value than previous studies had reported. Other manifestations 
(neurological, renal, cutaneous) occurred in similar frequencies, being in line with previous works, 
suggesting that the presence of hereditary thrombophilia did not change the presence of these 
involvements [1,16-18]  
  
Study Limitations 
We present a single center, retrospective study with the inherent limitations of this type of study 
design. Additionally, the limited number of the study sample undermines the study power. 
 
Conclusion 
Although with a significant prevalence in the studied sample, the presence of inherited 
thrombophilia displayed no categorical or particular clinical significance. These findings suggest that 
clinical manifestations in APS are mainly due to the APS itself, and that the presence of inherited 
thrombophilia do not significantly change the disease course.  
However, future research is needed, with larger study populations and ideally a prospective 
design, in order to categorically clarify the role of concomitant inherited thrombophilia on APS and the 
need to adjust treatment goals in this particular population. 
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Attachments 
 
  
Table III. Non clinical vascular manifestations of APS 
 
 
 
Table IV. Non clinical neurological manifestations of APS 
 
 
 
Table V. Immunological profile of APS-patients 
 
Other antibodies Nº of patients (%) 
ANA (n=75) 41 (54.7%) 
Anti-SSa (n=71) 6 (8.5%) 
Rheumatoid Factor (n=61) 3 (4.9%) 
Anti-SSb (n=71) 2 (2.8%) 
Anti-RNP (n=71) 1 (1.4%) 
ANCA (n=71) 1 (1.4%) 
Anti-centromere (n=71) 0 
Anti-Scl70 (n=71) 0 
 
 
 
 
 
Table VI. Prevalence of cardiovascular risk factor s among APS-patients 
 
Cardiovascular Risk Factor Nº of cases (%) 
Dyslipidemia (n=75) 29 (38.7%) 
Obesity (n=75) 19 (25.3%) 
Arterial Hypertension (n=75) 15 (20%) 
Smoker (n=75) 12 (16%) 
Hyperuricemia (n=75) 3 (4%) 
Diabetes (n=75) 3 (4%) 
 
 
 
Vascular Manifestations Nº of patients (%) 
Superficial Vein Thrombosis (n=75) 7 (9.3%) 
Cutaneous Ulcers/Necrosis (n=75) 5 (6.7%) 
Raynaud Phenomenon (n=75) 4 (5.3%) 
Livedo Reticularis (n=75) 1 (1.3%) 
Alveolar hemorrhage (n=75) 0 
Skin Pseudovasculitis (n=75) 0 
Neurological Manifestations Nº of patients (%) 
Migraine (n=75) 16 (21.3%) 
Seizures (n=75) 2 (6.7%) 
Memory lapses (n=75) 1 (1.3%) 
Cognitive impairment (n=75) 1 (1.3%) 
Transverse myelitis (n=75) 0 
Chorea (n=75) 0 
 
 
Table VII. Thrombotic events among APS-patients with thrombophilia 
 
Trombophilia 
 
Presence of 
one 
Thrombophilia 
(n=17) 
Antithrombin 
Deficiency 
(n=4) 
C-Protein 
Deficiency 
(n=4) 
S-Protein 
Deficiency 
(n=9) 
Leiden 
V 
Factor 
(n=1) 
RCPA 
(n=5) 
Prothrombin  
Gene 
Mutation  
(n=2) 
Clinical event 
Arterial 
Thrombosis 
n=2 p=0.720 n=0 n=1 p=1 n=2 p=1 n=0 n=0 n=0 
Venous 
Thrombosis 
n=12 p=0.572 n=3 p=1 n=3 p=1 n=5 p=0.707 
n=1 
p=1 
n=4 p=1 n=1 p=0.508 
Obstetric 
morbidity 
n=4 p=0.763 n=1 p=1 n=0 n=3 p=0.668 n=0 n=0 n=1 p=0.296 
Recurrence of 
thrombotic  events 
n=2 p=0.723 n=0 n=0 
n=3  
p=0-312 
n=0 
n=1 
p=0.554 
n=0 
 
 
 
 
Table VIII. Non criteria clinical events among APS-patients with thrombophilia 
 
Trombophilia 
 
Antithrombin 
Deficiency 
(n=4) 
C-Protein 
Deficiency 
(n=4) 
S-Protein 
Deficiency 
(n=9) 
Leiden 
V 
Factor 
(n=1) 
RCPA 
(n=5) 
Prothrombin 
Gene 
Mutation  
(n=2) 
 
Clinical event 
Vascular 
SVT 0 0 1 0 1 0 
Livedo reticularis 0 0 0 0 0 0 
Raynaud 0 2 1 0 1 0 
Cutaneous 
ulcers/necrosis 
0 0 1 0 0 0 
Hematological  Thrombocytopenia 1 1 1 0 1 0 
Cardiac Valvular dysfunction 0 0 0 0 0 0 
Neurological 
seizures 0 0 0 0 0 0 
Migraines 1 1 2 1 3 0 
Pulmonar 
Pulmonary 
Hypertension 
1 0 1 0 0 0 
Renal microangiopathy 1 0 1 0 1 0 
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